Allogene Therapeutics Reports $42.6 Million Net Loss in Q1 2026, Improves from Previous Year

Allogene Therapeutics, Inc. reported a net loss of $42.6 million for the first quarter of 2026, a significant improvement compared to a net loss of $59.7 million during the same period in 2025. The company's total operating expenses decreased by 29% to $46.1 million, down from $65.2 million in the prior year. This reduction was primarily driven by a 36% decrease in research and development expenses, which fell to $32.0 million from $50.2 million, reflecting a strategic shift in resource allocation and a decrease in personnel-related costs. General and administrative expenses also saw a slight decline, totaling $14.1 million compared to $15.0 million in the previous year.

In terms of financial position, Allogene's total assets decreased to $396.0 million as of March 31, 2026, down from $415.9 million at the end of 2025. The company reported cash and cash equivalents of $30.3 million, alongside short-term investments of $236.6 million. The decrease in cash reserves was attributed to ongoing operational expenses, although the company raised $20.7 million through at-the-market offerings during the quarter. Following a public offering in April 2026, Allogene expects to have sufficient capital to fund operations into the first quarter of 2029.

Strategically, Allogene has focused on advancing its clinical pipeline, particularly its lead product candidates, including cemacabtagene ansegedleucel (cema-cel) and ALLO-316. The company is currently conducting pivotal trials for cema-cel in patients with large B-cell lymphoma and has expanded its clinical trials globally, including sites in South Korea and Australia. Additionally, the company has made significant progress in its ALLO-316 program, which targets CD70 in renal cell carcinoma, and has received Regenerative Medicine Advanced Therapy designation from the FDA.

Operationally, Allogene has streamlined its workforce by approximately 28% as part of a strategic realignment to focus on its clinical programs. This workforce reduction is expected to yield long-term cost savings and enhance operational efficiency. As of March 31, 2026, the company had 244.8 million shares outstanding, reflecting an increase from 229.4 million shares at the end of 2025, primarily due to stock options and equity offerings.

Looking ahead, Allogene anticipates continued investment in research and development, with expectations of ongoing operating losses as it advances its clinical programs. The company remains committed to its goal of delivering innovative allogeneic T cell therapies for cancer and autoimmune diseases, while also exploring potential partnerships to enhance its development capabilities and market reach.